Localized Attention On A Global Scale: A Phase III Study In Early Alzheimer's

As a full-service, midsize CRO, Worldwide Clinical Trials can execute global studies while maintaining a boutique approach to our clients and giving individualized attention to clinical sites. In a recent Phase III study focusing on mild cognitive impairment (MCI) and mild Alzheimer’s disease, we worked with 250 sites across 14 countries in North America, Europe, and the Asia-Pacific region. We completed recruitment within 22 months, randomizing more than 1,800 subjects after screening more than 6,000 patients. The global pandemic introduced unanticipated disruption to recruitment, study visits, onsite monitoring, and more. Nevertheless, we persevered and even exceeded expectations in some cases.